Though still strug­gling, Bel­licum can re­sume tri­al on CAR-T hope­ful af­ter FDA lifts clin­i­cal hold

Af­ter a dis­as­trous 2020 that in­clud­ed ax­ing near­ly 80% of its staff amid strug­gling clin­i­cal re­sults for the few mol­e­cules re­main­ing in its pipeline, Hous­ton biotech Bel­licum fi­nal­ly got a piece of good news Thurs­day.

The FDA, Bel­licum said in a press re­lease, lift­ed a clin­i­cal hold on a Phase I/II tri­al of BPX-601 and rim­iducid — a treat­ment can­di­date for prostate and pan­cre­at­ic can­cer tu­mors — im­ple­ment­ed af­ter a pan­cre­at­ic can­cer pa­tient in the tri­al died in an ear­ly-stage test.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER